Hypopharyngeal Cancer - Pipeline Review, H2 2011

Global Markets Direct, August 2011, Pages: 61

Hypopharyngeal Cancer - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Hypopharyngeal Cancer - Pipeline Review, H2 2011', provides an overview of the Hypopharyngeal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Hypopharyngeal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypopharyngeal Cancer. 'Hypopharyngeal Cancer - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hypopharyngeal Cancer.
- A review of the Hypopharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypopharyngeal Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hypopharyngeal Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypopharyngeal Cancer pipeline depth and focus of Hypopharyngeal Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypopharyngeal Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Hypopharyngeal Cancer
Hypopharyngeal Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Hypopharyngeal Cancer Therapeutics - Products under Investigation by Universities/Institutes
Hypopharyngeal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Docetaxel + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + Cetuximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Erlotinib Hydrochloride + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin + Docetaxel + Fluorouracil + Lapatinib + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TS-1 + Nedaplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1 + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1 + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radiotherapy + cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Panitumumab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cisplatin + erlotinib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cisplatin + paclitaxel + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lapatinib Ditosylate + Capecitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Cisplatin + 5-Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypopharyngeal Cancer Therapeutics – Drug Profile Updates
Hypopharyngeal Cancer Therapeutics - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hypopharyngeal Cancer, H2 2011
Products under Development for Hypopharyngeal Cancer – Comparative Analysis, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Hypopharyngeal Cancer Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Hypopharyngeal Cancer, H2 2011
Products under Development for Hypopharyngeal Cancer – Comparative Analysis, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Bladder Cancer - Pipeline Review, H2 2012
• Cervical Cancer - Pipeline Review, H2 2012
• Lip Cancer - Pipeline Review, H2 2012
• Oral Cancer - Pipeline Review, H2 2012
• Brain Cancer - Pipeline Review, H2 2012
• Head And Neck Cancer - Pipeline Review, H2 2012
• Anaplastic Thyroid Cancer - Pipeline Review, H2 2012
• Oral Cavity (Mouth) Cancer - Pipeline Review, H2 2012
• Adenomas - Pipeline Review, H2 2012
• Metastatic Prostate Cancer - Pipeline Review, H2 2012